成年人费城染色体阳性急性淋巴细胞白血病治疗现状及展望  

Current status and prospects in treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

作　　者：赵美芳 谭业辉[1] Zhao Meifang;Tan Yehui

机构地区：[1]吉林大学第一医院血液科,长春130000

出　　处：《白血病．淋巴瘤》2020年第8期509-512,共4页Journal of Leukemia & Lymphoma

摘　　要：成年人费城染色体阳性急性淋巴细胞白血病(Ph^+ALL)传统化疗效果差,酪氨酸激酶抑制剂(TKI)的出现使Ph^+ALL治疗模式发生改变,改善了患者生存期。在TKI时代,关于下列问题仍未达成共识,如移植是否仍需要、移植前后TKI如何应用、免疫治疗又有哪些新进展及免疫联合靶向治疗效果如何,文章就Ph^+ALL治疗现状及展望进行综述。The effect of traditional chemotherapy on Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph^+ALL)in adults is not satisfactory.With the introduction of tyrosine kinase inhibitor(TKI),the treatment paradigms and overall survival of adult patients with Ph^+ALL have been improved.In the era of TKI,there is no consensus so far on the following issues,whether transplantation is still necessary,how to apply TKI before and after transplantation,what are the new advances in immunotherapy,and the effect of immunotherapy combined with targeted therapy.This article reviews the current treatment status and prospects in Ph^+ALL.

关 键 词：费城染色体 急性淋巴细胞白血病 酪氨酸磷酸酶抑制剂 免疫治疗 

分 类 号：R733.71[医药卫生—肿瘤]